|
|
Vaccine Detail
|
MDX-1379 (gp100) Melanoma Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: MDX-1379 (gp100) Melanoma Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: two gp100 peptides (NCT00094653)
- Immunization Route: subcutaneous injection
- Description: MDX-1379 is made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells. It could be given in combination with MDX-010 (ipilimumab, BMS-734016). MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation. (NCT00094653)
|
| Host Response |
|
|
| References |
NCT00094653: MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00094653]
|
|
